On September 7, 2018, the Guangdong-Hong Kong-Macao Greater Bay Area Biotech Innovation Development Summit and Top 50 Innovative Enterprises Awards Ceremony was held at the Guangzhou International Convention and Exhibition Center. Guangzhou DiQi Pharmaceuticals Co., Ltd was honored with the title of “2018 Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area”!

The selection of the Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area was jointly organized by KPMG China and the China Innovation Industry Research Institute. The judging panel comprised over twenty professionals from government agencies, third-party research institutions, specialized investment firms, and medical organizations. They comprehensively evaluated the technological innovation and future growth prospects of participating enterprises based on three dimensions: leading technology application and breakthroughs, market adoption, and valuation and capital market recognition.

As an innovative technology R&D CRO company, DiQi received unanimous recognition from judges at all levels during the selection process. First introduced during the 2017 Two Sessions, the Guangdong-Hong Kong-Macao Greater Bay Area concept has now been elevated to a national strategy. This urban cluster development strategy imposes higher demands on the biopharmaceutical industry while simultaneously offering exceptional growth opportunities. Since its inception, DiQi has been guided by its founding mission: to develop high-quality, effective, long-acting, and highly compliant medicines that are affordable for the public, and to become a leading enterprise in China's high-end pharmaceutical formulation sector. The DiQi team deeply understands the weight of this mission and responsibility. Moving forward, the company will leverage the resource advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, strive diligently, and make positive contributions to China's economic development!